Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DQ4FR9
|
|||
| Drug Name |
Fazirsiran
|
|||
| Drug Type |
RNA interference
|
|||
| Indication | Alpha-1 antitrypsin deficiency [ICD-11: 5C5A; ICD-10: E88.0, M79.3; ICD-9: 273.4] | Phase 3 | [1] | |
| Company |
TAKEDA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | SERPINA1 messenger RNA (SERPINA1 mRNA) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05677971) A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F2 to F4 Fibrosis. U.S.National Institutes of Health. | |||
| REF 2 | Fazirsiran for Liver Disease Associated with Alpha(1)-Antitrypsin Deficiency. N Engl J Med. 2022 Aug 11;387(6):514-524. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.